XNCR (Xencor) Inventories, Finished Goods: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XNCR Xencor Inc XNCR
46 GF Score
Price $19.44
GF Value $9.18
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Xencor Inventories, Finished Goods?

Xencor XNCR -0.41% 46 Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus rates XNCR with a GF Score™ of 46/100 and a GF Value™ of $9.18 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Xencor Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Xencor's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xencor Inventories, Finished Goods Chart

Xencor Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Xencor Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XNCR
46GF Score
Xencor Inc XNCR
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xencor Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.00 Mil mean?
Xencor (XNCR) has a Inventories, Finished Goods of $0.00 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Xencor and its competitors.
Is Xencor's Inventories, Finished Goods too high?
Xencor's current Inventories, Finished Goods is $0.00 Mil. Overall, Xencor has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xencor's Inventories, Finished Goods compare to MGTX and WVE?
Xencor's Inventories, Finished Goods of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Xencor and its competitors. Xencor's current Inventories, Finished Goods is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xencor stock overvalued right now?
Based on GuruFocus' analysis, Xencor (XNCR) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.18, compared to a current price of $19.44 — trading 111.8% above its estimated fair value. The current Inventories, Finished Goods is $0.00 Mil. Xencor's overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Xencor (XNCR), the current Inventories, Finished Goods is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xencor (XNCR) Overvalued in 2026?

Based on GuruFocus' analysis, Xencor stock appears to be overvalued. The current stock price of $19.44 is trading 111.8% above its estimated GF Value™ of $9.18. GuruFocus considers Xencor to be Significantly Overvalued.

Key valuation signals for XNCR:

  • Inventories, Finished Goods: $0.00 Mil
  • GF Value™: $9.18 vs. price of $19.44 (111.8% above fair value)
  • GF Score™: 46/100 with 8 warning signs

No single metric tells the full story. See the XNCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xencor Business Description

Other Exchanges XE9:Germany
Address 465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
46GF Score

Get the complete analysis for XNCR

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.44
Price
$9.18
GF Value